p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure–Function Continuum Concept

Although it is one of the most studied proteins, p53 continues to be an enigma. This protein has numerous biological functions, possesses intrinsically disordered regions crucial for its functionality, can form both homo-tetramers and isoform-based hetero-tetramers, and is able to interact with many binding partners. It contains numerous posttranslational modifications, has several isoforms generated by alternative splicing, alternative promoter usage or alternative initiation of translation, and is commonly mutated in different cancers. Therefore, p53 serves as an important illustration of the protein structure–function continuum concept, where the generation of multiple proteoforms by various mechanisms defines the ability of this protein to have a multitude of structurally and functionally different states. Considering p53 in the light of a proteoform-based structure–function continuum represents a non-canonical and conceptually new contemplation of structure, regulation, and functionality of this important protein.

[1]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[2]  A. Joachimiak,et al.  Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. , 2006, Genes & development.

[3]  D. Bashford,et al.  Monitoring Ligand-Induced Protein Ordering in Drug Discovery. , 2016, Journal of molecular biology.

[4]  H. Dyson,et al.  Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. , 1999, Journal of molecular biology.

[5]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[6]  Y Taya,et al.  DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization , 1999, The EMBO journal.

[7]  J. Lukin,et al.  Molecular basis of Pirh2-mediated p53 ubiquitylation , 2008, Nature Structural &Molecular Biology.

[8]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[9]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[10]  D. Huhn,et al.  Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. , 1993, Leukemia.

[11]  M. Olivier,et al.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. , 2007, Cancer letters.

[12]  A. Wellstein,et al.  Dietary downregulation of mutant p53 levels via glucose restriction , 2012, Cell cycle.

[13]  Allen P. Minton,et al.  Cell biology: Join the crowd , 2003, Nature.

[14]  P. Tompa.  Intrinsically unstructured proteins. , 2002, Trends in biochemical sciences.

[15]  Thierry Soussi,et al.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis , 2012, Nucleic Acids Res..

[16]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[17]  Zsuzsanna Dosztányi,et al.  Prediction of Protein Binding Regions in Disordered Proteins , 2009, PLoS Comput. Biol..

[18]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[19]  K. Sakaguchi,et al.  Calcium-dependent Interaction of S100B with the C-terminal Domain of the Tumor Suppressor p53* , 1999, The Journal of Biological Chemistry.

[20]  D. Koshland.  Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. Uversky.  Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes. , 2011, Chemical Society reviews.

[22]  A. Wlodawer,et al.  Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. , 2009, Biochemistry.

[23]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[24]  H. Dyson,et al.  Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein , 2016, Proceedings of the National Academy of Sciences.

[25]  P. Tompa,et al.  Introducing protein intrinsic disorder. , 2014, Chemical reviews.

[26]  Wei Gu,et al.  p53 post-translational modification: deregulated in tumorigenesis. , 2010, Trends in molecular medicine.

[27]  J. Onuchic,et al.  Protein folding funnels: the nature of the transition state ensemble. , 1996, Folding & design.

[28]  Alan R. Fersht,et al.  Solution structure of p53 core domain: Structural basis for its instability , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Harris,et al.  Distinct pattern of p53 phosphorylation in human tumors , 2001, Oncogene.

[30]  C. Anderson,et al.  Mutant TP53 Posttranslational Modifications: Challenges and Opportunities , 2014, Human mutation.

[31]  Zoran Obradovic,et al.  Optimizing Long Intrinsic Disorder Predictors with Protein Evolutionary Information , 2005, J. Bioinform. Comput. Biol..

[32]  E. Fischer.  Einfluss der Configuration auf die Wirkung der Enzyme , 1894 .

[33]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[34]  A. Keith Dunker,et al.  The case for intrinsically disordered proteins playing contributory roles in molecular recognition without a stable 3D structure , 2013, F1000 biology reports.

[35]  Marc S. Cortese,et al.  Analysis of molecular recognition features (MoRFs). , 2006, Journal of molecular biology.

[36]  Sam W. Lee,et al.  The guardian of the genome , 2015, Science.

[37]  R. Ellis.  Macromolecular crowding : obvious but underappreciated , 2022 .

[38]  C M Dobson,et al.  Effects of macromolecular crowding on protein folding and aggregation , 1999, The EMBO journal.

[39]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[40]  A. Minton,et al.  Macromolecular crowding: biochemical, biophysical, and physiological consequences. , 1993, Annual review of biophysics and biomolecular structure.

[41]  P. Hainaut,et al.  ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53 , 2002, Oncogene.

[42]  Roberto Sanchez,et al.  Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.

[43]  V. Uversky,et al.  Ordered Disorder of the Astrocytic Dystrophin-Associated Protein Complex in the Norm and Pathology , 2013, PloS one.

[44]  J. Onuchic,et al.  Theory of Protein Folding This Review Comes from a Themed Issue on Folding and Binding Edited Basic Concepts Perfect Funnel Landscapes and Common Features of Folding Mechanisms , 2022 .

[45]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[46]  Lukasz Kurgan,et al.  Exceptionally abundant exceptions: comprehensive characterization of intrinsic disorder in all domains of life , 2014, Cellular and Molecular Life Sciences.

[47]  H. Dyson,et al.  Coupling of folding and binding for unstructured proteins. , 2002, Current opinion in structural biology.

[48]  Xuan Liu,et al.  Stimulation of p53 DNA Binding by c-Abl Requires the p53 C Terminus and Tetramerization , 2000, Molecular and Cellular Biology.

[49]  J. Bourdon,et al.  Expression of p53 isoforms in squamous cell carcinoma of the head and neck. , 2007, European journal of cancer.

[50]  Silvio C. E. Tosatto,et al.  ESpritz: accurate and fast prediction of protein disorder , 2012, Bioinform..

[51]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[52]  Ricardo E. Perez,et al.  Restoration of DNA‐binding and growth‐suppressive activity of mutant forms of p53 via a PCAF‐mediated acetylation pathway , 2010, Journal of cellular physiology.

[53]  D. Meek,et al.  Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. , 2001, The Biochemical journal.

[54]  A. Fersht,et al.  Quaternary structures of tumor suppressor p53 and a specific p53–DNA complex , 2007, Proceedings of the National Academy of Sciences.

[55]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[56]  E. Appella,et al.  SIGNALING TO THE P53 TUMOR SUPPRESSOR THROUGH PATHWAYS ACTIVATED BY GENOTOXIC AND NON-GENOTOXIC STRESSES. , 2002 .

[57]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[58]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. Appella,et al.  Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.

[60]  Peter Tompa,et al.  Unstructural biology coming of age. , 2011, Current opinion in structural biology.

[61]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[62]  V. Uversky.  Disordered competitive recruiter: fast and foldable. , 2012, Journal of molecular biology.

[63]  Joelle N Pelletier,et al.  Protein motions promote catalysis. , 2004, Chemistry & biology.

[64]  M. McNutt,et al.  An ATM- and Rad3-related (ATR) Signaling Pathway and a Phosphorylation-Acetylation Cascade Are Involved in Activation of p53/p21Waf1/Cip1 in Response to 5-Aza-2′-deoxycytidine Treatment* , 2008, Journal of Biological Chemistry.

[65]  P. Boffetta,et al.  Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation , 2005, Journal of Medical Genetics.

[66]  Marc S. Cortese,et al.  Coupled folding and binding with alpha-helix-forming molecular recognition elements. , 2005, Biochemistry.

[67]  Peter E Wright,et al.  Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. , 2010, Biochemistry.

[68]  M. Fiscella,et al.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  P. Hainaut,et al.  DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. , 2002, Oncogene.

[70]  Judith Herzfeld,et al.  Life in a crowded world , 2004, EMBO reports.

[71]  I. Bahar,et al.  Coupling between catalytic site and collective dynamics: a requirement for mechanochemical activity of enzymes. , 2005, Structure.

[72]  Paul Tempst,et al.  Regulation of p53 activity through lysine methylation , 2004, Nature.

[73]  L. Iakoucheva,et al.  The importance of intrinsic disorder for protein phosphorylation. , 2004, Nucleic acids research.

[74]  W. Mcdougal.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.

[75]  R. Apweiler,et al.  Finding one's way in proteomics: a protein species nomenclature , 2009, Chemistry Central journal.

[76]  V. Uversky.  (Intrinsically disordered) splice variants in the proteome: implications for novel drug discovery , 2016, Genes & Genomics.

[77]  Hans Frauenfelder,et al.  Temperature-dependent X-ray diffraction as a probe of protein structural dynamics , 1979, Nature.

[78]  K. Vousden,et al.  Regulation of the p53 pathway by ubiquitin and related proteins. , 2010, The international journal of biochemistry & cell biology.

[79]  V. Lang,et al.  Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation. , 2010, The international journal of biochemistry & cell biology.

[80]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[81]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[82]  C. Brown,et al.  Intrinsic protein disorder in complete genomes. , 2000, Genome informatics. Workshop on Genome Informatics.

[83]  P. Agarwal,et al.  Network of coupled promoting motions in enzyme catalysis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. Thompson,et al.  p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients , 2011, Breast Cancer Research.

[85]  Zoran Obradovic,et al.  The protein trinity—linking function and disorder , 2001, Nature Biotechnology.

[86]  Karen H. Vousden,et al.  Modifications of p53: competing for the lysines. , 2009, Current opinion in genetics & development.

[87]  R. Fåhraeus,et al.  Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47 , 2008, Cell cycle.

[88]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[89]  A Keith Dunker,et al.  Characterization of molecular recognition features, MoRFs, and their binding partners. , 2007, Journal of proteome research.

[90]  F. Jiang,et al.  Crystallographic structure of a small molecule SIRT1 activator-enzyme complex , 2014, Nature Communications.

[91]  A Keith Dunker,et al.  Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. S. Sodhi,et al.  Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. , 2004, Journal of molecular biology.

[93]  E. Domany,et al.  Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop , 2011, Cell cycle.

[94]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[95]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[96]  D. A. Bosco,et al.  Enzyme Dynamics During Catalysis , 2002, Science.

[97]  L. Strong,et al.  A germline missense mutation R337C in exon 10 of the human p53 gene , 1998, Human mutation.

[98]  Eric W Deutsch,et al.  State of the human proteome in 2013 as viewed through PeptideAtlas: comparing the kidney, urine, and plasma proteomes for the biology- and disease-driven Human Proteome Project. , 2014, Journal of proteome research.

[99]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[100]  A. Fersht,et al.  Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain , 2008, Proceedings of the National Academy of Sciences.

[101]  V. Uversky,et al.  The protein kingdom extended: ordered and intrinsically disordered proteins, their folding, supramolecular complex formation, and aggregation. , 2010, Progress in biophysics and molecular biology.

[102]  Matthew A. Watson,et al.  HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. , 2012, Structure.

[103]  H Frauenfelder,et al.  Structural dynamics of liganded myoglobin. , 1980, Biophysical journal.

[104]  J. Garber,et al.  Germline TP53 Mutations and the Changing Landscape of Li–Fraumeni Syndrome , 2014, Human mutation.

[105]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[106]  Vladimir N Uversky,et al.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. , 2014, Chemical reviews.

[107]  Naoko Okumura,et al.  Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. , 2011, Biochemical and biophysical research communications.

[108]  Wei Gu,et al.  Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. , 2003, Current opinion in cell biology.

[109]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[110]  R. Fåhraeus,et al.  Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. , 2010, Molecular cell.

[111]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[112]  T. Libermann,et al.  Blockage of NF-κB Induces Serine 15 Phosphorylation of Mutant p53 by JNK Kinase in Prostate Cancer Cells , 2005 .

[113]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[114]  V. Rotter,et al.  Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies , 2011, Cancer Gene Therapy.

[115]  Y. Nishimura,et al.  Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53. , 2014, Journal of the American Chemical Society.

[116]  Bin Xue,et al.  Archaic chaos: intrinsically disordered proteins in Archaea , 2010, BMC Systems Biology.

[117]  A. Fersht,et al.  Modulation of the Oligomerization State of p53 by Differential Binding of Proteins of the S100 Family to p53 Monomers and Tetramers♦ , 2009, Journal of Biological Chemistry.

[118]  Arieh Warshel,et al.  Dynamical contributions to enzyme catalysis: critical tests of a popular hypothesis. , 2006, Chemical reviews.

[119]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[120]  C. Arrowsmith,et al.  Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[121]  A. Strasser,et al.  How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? , 2007, Cell Death and Differentiation.

[122]  V. Uversky.  Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators , 2014, Front. Mol. Biosci..

[123]  J. Bourdon,et al.  The isoforms of the p53 protein. , 2010, Cold Spring Harbor perspectives in biology.

[124]  E. Appella,et al.  Structural plasticity of methyllysine recognition by the tandem tudor domain of 53BP1. , 2015, Structure.

[125]  M. Groudine,et al.  An acetyl-methyl switch drives a conformational change in p53. , 2015, Structure.

[126]  J. Varley,et al.  Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family , 1997, Oncogene.

[127]  Predrag Radivojac,et al.  The structural and functional signatures of proteins that undergo multiple events of post‐translational modification , 2014, Protein science : a publication of the Protein Society.

[128]  D. Meek,et al.  Protein kinase CK1 is a p53‐threonine 18 kinase which requires prior phosphorylation of serine 15 , 1999, FEBS letters.

[129]  Shili Duan,et al.  Molecular recognition of p53 and MDM2 by USP7/HAUSP , 2006, Nature Structural &Molecular Biology.

[130]  Christopher J. Oldfield,et al.  Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. , 2007, Journal of proteome research.

[131]  Gary D Bader,et al.  A draft map of the human proteome , 2014, Nature.

[132]  A. Geist,et al.  Protein dynamics and enzymatic catalysis: investigating the peptidyl-prolyl cis-trans isomerization activity of cyclophilin A. , 2004, Biochemistry.

[133]  H Frauenfelder,et al.  Solvent viscosity and protein dynamics. , 1980, Biochemistry.

[134]  A Keith Dunker,et al.  Unfoldomics of human diseases: linking protein intrinsic disorder with diseases , 2009, BMC Genomics.

[135]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[136]  Z. Obradovic,et al.  Identification and functions of usefully disordered proteins. , 2002, Advances in protein chemistry.

[137]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[138]  D. Lane,et al.  Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity , 2011, Cell Death and Differentiation.

[139]  D. Lane,et al.  The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression , 2013, Oncogene.

[140]  A. Warshel,et al.  How important are entropic contributions to enzyme catalysis? , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[141]  A Keith Dunker,et al.  Alternative splicing of intrinsically disordered regions and rewiring of protein interactions. , 2013, Current opinion in structural biology.

[142]  M. Murphy,et al.  Genetic Modifiers of the p53 Pathway. , 2016, Cold Spring Harbor perspectives in medicine.

[143]  Wei-Guo Zhu,et al.  Surf the Post-translational Modification Network of p53 Regulation , 2012, International journal of biological sciences.

[144]  Nigel S Scrutton,et al.  A new conceptual framework for enzyme catalysis. Hydrogen tunnelling coupled to enzyme dynamics in flavoprotein and quinoprotein enzymes. , 2002, European journal of biochemistry.

[145]  V. Uversky.  Natively unfolded proteins: A point where biology waits for physics , 2002, Protein science : a publication of the Protein Society.

[146]  Obradovic,et al.  Predicting Protein Disorder for N-, C-, and Internal Regions. , 1999, Genome informatics. Workshop on Genome Informatics.

[147]  Christopher J. Oldfield,et al.  Intrinsically disordered proteins in human diseases: introducing the D2 concept. , 2008, Annual review of biophysics.

[148]  Alex Bateman,et al.  Tissue-Specific Splicing of Disordered Segments that Embed Binding Motifs Rewires Protein Interaction Networks , 2012, Molecular cell.

[149]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[150]  Kengo Kinoshita,et al.  PrDOS: prediction of disordered protein regions from amino acid sequence , 2007, Nucleic Acids Res..

[151]  Yili Yin,et al.  p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products , 2002, Nature Cell Biology.

[152]  Christopher J. Oldfield,et al.  Intrinsic disorder and functional proteomics. , 2007, Biophysical journal.

[153]  Amanda K. Frank,et al.  The tetramerization domain of p53 is required for efficient BAK oligomerization , 2007, Cancer biology & therapy.

[154]  Marc S. Cortese,et al.  Coupled folding and binding with α-helix-forming molecular recognition elements , 2005 .

[155]  A Keith Dunker,et al.  Intrinsic disorder and protein function. , 2002, Biochemistry.

[156]  P. Radivojac,et al.  PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .

[157]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[158]  Virginia M. Burger,et al.  Intrinsically Disordered Proteins: Where Computation Meets Experiment , 2014 .

[159]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[160]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[161]  J. Sarkaria,et al.  p53 isoform profiling in glioblastoma and injured brain , 2013, Oncogene.

[162]  Borivoj Vojtesek,et al.  Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin , 2008, Clinical Cancer Research.

[163]  Roland L. Dunbrack,et al.  PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. , 2010, Biochimica et biophysica acta.

[164]  Vladimir N Uversky,et al.  What does it mean to be natively unfolded? , 2002, European journal of biochemistry.

[165]  Christopher J. Oldfield,et al.  Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners , 2008, BMC Genomics.

[166]  D. Livingston,et al.  Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. , 2002, Genes & development.

[167]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[168]  Lloyd M. Smith,et al.  Proteoform: a single term describing protein complexity , 2013, Nature Methods.

[169]  F. Parak,et al.  Dynamics of metmyoglobin crystals investigated by nuclear gamma resonance absorption. , 1981, Journal of molecular biology.

[170]  Ettore Appella,et al.  p53 N-terminal phosphorylation: a defining layer of complex regulation. , 2012, Carcinogenesis.

[171]  T. Soussi,et al.  Splice mutations in the p53 gene: case report and review of the literature , 2003, Human mutation.

[172]  D. Meek,et al.  Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2 , 1999, The EMBO journal.

[173]  A K Dunker,et al.  Protein disorder and the evolution of molecular recognition: theory, predictions and observations. , 1998, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[174]  K. Sakaguchi,et al.  Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase , 2000, The Journal of Biological Chemistry.

[175]  A. Minton,et al.  Protein folding: Thickening the broth , 2000, Current Biology.

[176]  Dario Cattaneo,et al.  Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. , 2008, European journal of cancer.

[177]  SeJin Kim,et al.  Role of p53 isoforms and aggregations in cancer , 2016, Medicine.

[178]  K. Sakaguchi,et al.  Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. , 2008, Journal of molecular biology.

[179]  V. Uversky.  A decade and a half of protein intrinsic disorder: Biology still waits for physics , 2013, Protein science : a publication of the Protein Society.

[180]  J. Onuchic,et al.  Theory of protein folding: the energy landscape perspective. , 1997, Annual review of physical chemistry.

[181]  Zsuzsanna Dosztányi,et al.  ANCHOR: web server for predicting protein binding regions in disordered proteins , 2009, Bioinform..

[182]  M. Bolognesi,et al.  Function and Structure of Inherently Disordered Proteins This Review Comes from a Themed Issue on Proteins Edited Prediction of Non-folding Proteins and Regions Frequency of Disordered Regions Protein Evolution Partitioning Unstructured Proteins and Regions into Groups Involvement of Inherently Diso , 2022 .

[183]  D. Eisenberg,et al.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. , 2016, Cancer cell.

[184]  D. V. van Aalten,et al.  Synergy of Peptide and Sugar in O-GlcNAcase Substrate Recognition , 2012, Chemistry & biology.

[185]  M. Weyand,et al.  Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism , 2013, Proceedings of the National Academy of Sciences.

[186]  C. Anderson,et al.  Posttranslational modification of p53: cooperative integrators of function. , 2009, Cold Spring Harbor perspectives in biology.

[187]  L. Kay,et al.  Intrinsic dynamics of an enzyme underlies catalysis , 2005, Nature.

[188]  S. Emamzadah,et al.  Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein. , 2014, Journal of molecular biology.

[189]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[190]  Christopher J. Oldfield,et al.  Classification of Intrinsically Disordered Regions and Proteins , 2014, Chemical reviews.

[191]  Marc S. Cortese,et al.  Flexible nets , 2005, The FEBS journal.

[192]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[193]  J. Bourdon.  p53 Family isoforms. , 2007, Current pharmaceutical biotechnology.

[194]  A. S. Moraes,et al.  Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift , 2016, Oncology.

[195]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[196]  Maria Miller,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.

[197]  S. Zimmerman,et al.  Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. , 1991, Journal of molecular biology.

[198]  David M. Thomas,et al.  High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort , 2013, PloS one.

[199]  P. Agarwal.  Role of protein dynamics in reaction rate enhancement by enzymes. , 2005, Journal of the American Chemical Society.

[200]  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. , 1998, The EMBO journal.

[201]  H. Ke,et al.  p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation* , 2009, Journal of Biological Chemistry.

[202]  A Keith Dunker,et al.  Natively Disordered Proteins , 2004, Applied bioinformatics.

[203]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[204]  A. Bussard.  A scientific revolution? , 2005, EMBO reports.

[205]  Christopher J. Oldfield,et al.  Intrinsically disordered protein. , 2001, Journal of molecular graphics & modelling.

[206]  P. Romero,et al.  Natively Disordered Proteins , 2008, Applied bioinformatics.

[207]  P. Chène,et al.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.

[208]  Peter Tompa,et al.  The functional benefits of protein disorder , 2003 .

[209]  H. Frauenfelder,et al.  A unified model of protein dynamics , 2009, Proceedings of the National Academy of Sciences.

[210]  A. Minton,et al.  Influence of excluded volume upon macromolecular structure and associations in 'crowded' media. , 1997, Current opinion in biotechnology.

[211]  G. Petsko,et al.  Conformational substates in a protein: structure and dynamics of metmyoglobin at 80 K. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[212]  R. Fåhraeus,et al.  p53 isoforms gain functions , 2010, Oncogene.

[213]  J. Bourdon,et al.  p53 Isoforms: An Intracellular Microprocessor? , 2011, Genes & cancer.

[214]  G. W. Beadle,et al.  Genic Control of Biochemical Reactions in Neurospora , 1945, The American Naturalist.

[215]  J. Milner,et al.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53 , 2011, Cancer biology & therapy.

[216]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[217]  R. Zeillinger,et al.  Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer , 2010, Oncogene.

[218]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[219]  David J. Weber,et al.  Structure of the negative regulatory domain of p53 bound to S100B(ββ) , 2000, Nature Structural Biology.

[220]  C. Wolberger,et al.  Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. , 2005, Molecular cell.

[221]  Eric W Deutsch,et al.  The state of the human proteome in 2012 as viewed through PeptideAtlas. , 2013, Journal of proteome research.

[222]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[223]  H Frauenfelder,et al.  Dynamics of ligand binding to myoglobin. , 1975, Biochemistry.

[224]  P G Wolynes,et al.  Protein folding mechanisms and the multidimensional folding funnel , 1998, Proteins.

[225]  A. Dunker,et al.  Understanding protein non-folding. , 2010, Biochimica et biophysica acta.

[226]  K. Sakaguchi,et al.  Tetramer formation of tumor suppressor protein p53: Structure, function, and applications , 2016, Biopolymers.

[227]  Virginie Marcel,et al.  Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript , 2010, FEBS letters.

[228]  A. Fersht,et al.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2 , 2009, Oncogene.

[229]  V. Uversky,et al.  Protein folding revisited. A polypeptide chain at the folding – misfolding – nonfolding cross-roads: which way to go? , 2003, Cellular and Molecular Life Sciences CMLS.

[230]  Toshiaki Hara,et al.  Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. , 2006, Molecular cell.

[231]  Sanjeeva Srivastava,et al.  The quest of the human proteome and the missing proteins: digging deeper. , 2015, Omics : a journal of integrative biology.

[232]  A. Fulton,et al.  How crowded is the cytoplasm? , 1982, Cell.

[233]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[234]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[235]  S. Benkovic,et al.  Preorganization and protein dynamics in enzyme catalysis. , 2002, Chemical record.

[236]  D. Phillips,et al.  Crystallographic studies of the dynamic properties of lysozyme , 1979, Nature.

[237]  E. Pinto,et al.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[238]  Nina Anensen,et al.  A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[239]  J. Onuchic,et al.  Protein folding funnels: a kinetic approach to the sequence-structure relationship. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[240]  Ettore Appella,et al.  ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation* , 2002, The Journal of Biological Chemistry.

[241]  J. Espinosa,et al.  The impact of post-transcriptional regulation in the p53 network , 2012, Briefings in functional genomics.

[242]  J. Bourdon,et al.  Uncovering the role of p53 splice variants in human malignancy: a clinical perspective , 2013, OncoTargets and therapy.

[243]  D. Lane,et al.  Detecting p53 isoforms at protein level. , 2013, Methods in molecular biology.

[244]  A Keith Dunker,et al.  Signal transduction via unstructured protein conduits. , 2008, Nature chemical biology.

[245]  T. Limpaiboon,et al.  Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. , 2013, International journal of oncology.

[246]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[247]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[248]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[249]  V. Uversky,et al.  Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.

[250]  Lukasz A. Kurgan,et al.  D2P2: database of disordered protein predictions , 2012, Nucleic Acids Res..

[251]  Andrew Shenton,et al.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.

[252]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[253]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[254]  Jidong Zhu,et al.  Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation* , 2011, The Journal of Biological Chemistry.

[255]  K. Okaichi,et al.  Phosphorylation of p53 modifies sensitivity to ionizing radiation. , 2011, Anticancer research.

[256]  H. Kayserili,et al.  LI-FRAUMENI SYNDROME IN A TURKISH FAMILY , 2010, Pediatric hematology and oncology.

[257]  L. Iakoucheva,et al.  Intrinsic disorder in cell-signaling and cancer-associated proteins. , 2002, Journal of molecular biology.

[258]  V. Uversky.  Unusual biophysics of intrinsically disordered proteins. , 2013, Biochimica et biophysica acta.

[259]  Christian Ottmann,et al.  Structure of the p53 C‐terminus bound to 14‐3‐3: Implications for stabilization of the p53 tetramer , 2010, FEBS letters.

[260]  Zoran Obradovic,et al.  Length-dependent prediction of protein intrinsic disorder , 2006, BMC Bioinformatics.

[261]  Wei Song,et al.  Expression of p53 isoforms in renal cell carcinoma. , 2009, Chinese medical journal.